You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨中國醫療集團逆勢大漲近8% 關聯企業獲得抗病毒產品邁可欣生產註冊批准
格隆匯 03-06 09:52
格隆匯3月6日丨中國醫療集團(8225.HK)今日逆勢高開,開盤衝高後回落,現漲7.79%,報0.83港元,暫成交428.4萬港元,最新總市值8.2億港元。中國醫療集團公佈,集團關聯製造企業於2020年2月25日獲得抗病毒產品邁可欣(利托那韋口服液)國藥準字H20051019生產註冊批准後,收到多國採購需求,集團擬與一家加拿大公司開展國際生物等效性試驗和國際註冊。由於新冠病毒在中國境外已經涉及73個國家,據查目前全球生產利托那韋製劑的企業只有兩家。另外,日前公司抗痴呆藥“喜恩卡片劑”獲國家藥監局註冊批准,其中喜恩卡片是全球第一個上市的片劑。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account